Variation in use of targeted therapies for metastatic renal cell carcinoma: Results from a Dutch population-based registry

10.1186/s12885-016-2395-x ; BMC Cancer ; 16 ; 1 ; 364

Volltext
Verfasser: De Groot, S
Sleijfer, S
Redekop, W.K
Oosterwijk, E
Haanen, J.B.A.G
Kiemeney, L.A.L.M
Uyl-de Groot, C.A
Dokumenttyp: Artikel
Erscheinungsdatum: 2016
Schlagwörter: alpha interferon / bevacizumab / everolimus / pazopanib / sorafenib / sunitinib / temsirolimus / antineoplastic agent / indole derivative / pyrimidine derivative / pyrrole derivative / sulfonamide / adult / age / aged / Article / bone metastasis / brain metastasis / cancer prognosis / cancer registry / cancer survival / clinical effectiveness / clinical practice / cohort analysis / controlled study / drug use / drug utilization / female / high risk population / human / kidney carcinoma / liver metastasis / lung metastasis / major clinical study / male / metastasis / metastasis resection / molecularly targeted therapy / nephrectomy / Netherlands / number of metastatic site / oncological parameters / overall survival / survival time / systemic therapy / trend study / Carcinoma / Renal Cell
Sprache: unknown
Permalink: https://search.fid-benelux.de/Record/base-28997747
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://scholarbank.nus.edu.sg/handle/10635/181363